Evidence map›Paper›PMID 30537165›Full record

ArticleJournal of cellular physiology2019

Long noncoding RNA Breast cancer antiestrogen resistance 4 is associated with cancer progression and its significant prognostic value.

Wenqiu Zhao, Zhenlin Wang, Xiao Fang, Na Li, Jian Fang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Wenqiu ZhaoDepartment of Clinical Laboratory, Xuzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Xuzhou, Jiangsu, China.
Zhenlin WangDepartment of Neurosurgery, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiao FangDepartment of Orthopaedic, Hefei Orthopaedics Hospital, Hefei, Anhui, China.
Na LiDepartment of transfusion, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Jian FangDepartment of transfusion, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.ORCID 0000-0001-7598-1091
Anhui Medical University · CNAnhui Mental Health Center · CNJiangsu University · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer antiestrogen resistance 4 (BCAR4) is a novel long noncoding RNA. It was originally identified in a screen for genes responsible for the development of resistance to antiestrogens in breast cancer cells and plays a major role in various tumors. However, the clinical diagnostic role of BCAR4 in tumors is not completely understood. This current meta-analysis aimed to comprehensively explore the potential role of BCAR4 as a prognostic biomarker in a number of cancers. Five public databases PubMed, EMBASE, Web of Science, Wiley Online Library, and Medline were used to search for articles. Nine studies comprising 1,293 patients were included in this meta-analysis. The results of analysis showed that BCAR4 expression in human cancer was significantly associated with poor overall survival (hazard ratio [HR] = 1.98, confidence interval [CI]: [1.71-2.29]), p < 0.00001, and high BCAR4 expression was associated with clinical stage (OR and its 95% CI was 3.30 [1.99-5.46], p < 0.00001), distant metastasis (OR = 3.83, 95% CI: 2.15-6.82, p < 0.00001), and lymph node metastasis (OR and its 95% CI was 2.91 [1.62-5.25], p = 0.0004) in patients with cancer. Furthermore, the results revealed the prognostic significance of BCAR4 in gastrointestinal malignancy, breast cancer, and osteosarcoma (HR and its 95% CI were 2.05 [1.56-2.68], p < 0.00001; 1.78 [1.46-2.16], p < 0.00001; and 2.47 [1.41-4.34], p < 0.00001, respectively). This meta-analysis indicated the potential value of BCAR4 as a biomarker for predicting a poor prognosis in patients with cancer.

Indexed as

Biomarkers, TumorBreast NeoplasmsGene Expression Regulation, NeoplasticHumansLymphatic MetastasisNeoplasmsOsteosarcomaPrognosisRNA, Long NoncodingBCAR4 non-coding RNA, humanBiomarkers, TumorRNA, Long NoncodingBCAR4cancerclinical outcomeprognosis

Identifiers

PMID30537165
PMCPMC13483275
OpenAlexW2904719783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.